Clinical Trials Sponsored by Rigel Pharmaceuticals

Total 20034 results

ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx

United States, Israel, Belgium, Germany, Spain, United Kingdom, Italy, France, Czechia
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Terminated

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Rett Syndrome | RTT

United States, Canada, Italy, Spain, United Kingdom, Australia
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
NovaBay Pharmaceuticals, Inc.
Novum Pharmaceutical Research Services; International Dermatology Research,...

Completed

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

Impetigo

Dominican Republic
PETHEMA Foundation
Millennium Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research...

Completed

Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

Multiple Myeloma

Spain
Douglas Pharmaceuticals America Ltd
Novum Pharmaceutical Research Services; ACM Global Laboratories

Completed

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

Tinea Pedis

Belize, United States
University of Michigan Rogel Cancer Center
Augusta University

Withdrawn

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Non-Small Cell Lung Cancer

United States
University of Michigan Rogel Cancer Center
Genentech, Inc.

Terminated

Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Loco-regional Esophageal Cancer
University of Michigan Rogel Cancer Center
Genentech, Inc.

Completed

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

HER-2 Positive Metastatic Breast Cancer

United States
University of Michigan Rogel Cancer Center
Genentech, Inc.

Not yet recruiting

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia

United States
Bobbie Jo Rimel, MD

Recruiting

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

Recurrent Ovarian Cancer | Platinum-sensitive Ovarian Cancer

United States
University of Michigan Rogel Cancer Center
NRG Oncology

Completed

An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer Survivors

Cancer-related Cognitive Impairment | Breast Cancer Survivorship

United States
University of Michigan Rogel Cancer Center
Amgen; Mallinckrodt

Completed

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Graft Versus Host Disease

United States
University of Michigan Rogel Cancer Center
Celgene Corporation

Terminated

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Bladder Cancer | Urothelial Cancer

United States
University of Michigan Rogel Cancer Center
Genentech, Inc.

Completed

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Urologic Neoplasms

United States
Lynn Henry

Completed

A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy

Breast Cancer

United States
University of Michigan Rogel Cancer Center
Sanofi-Synthelabo

Completed

Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer

Pancreatic Neoplasms

United States
Lynn Henry

Completed

Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients

Pain | Breast Cancer

United States
Lynn Henry

Completed

Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms

Breast Cancer | Arthralgia

United States
University of Michigan Rogel Cancer Center
Celgene Corporation

Completed

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Bladder Cancer

United States
Regeneron Pharmaceuticals
ISA Pharmaceuticals B.V.

Active, not recruiting

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Cervical Cancer

Spain, Korea, Republic of, Netherlands, Brazil, Belgium, United States, Italy, Russian Federation
Ligand Pharmaceuticals
CyDex Pharmaceuticals, Inc.

Withdrawn

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Contrast-induced Nephropathy
Paratek Pharmaceuticals Inc
Novartis Pharmaceuticals

Terminated

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (CSSI)

Skin Diseases, Infectious

United States
Vertex Pharmaceuticals Incorporated
Janssen Pharmaceuticals

Terminated

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Hepatitis C

United States, United Kingdom, Spain, Belgium, Italy, Germany
Eleison Pharmaceuticals LLC.
Threshold Pharmaceuticals

Completed

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Novartis Pharmaceuticals
Vanda Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

Schizophrenia

United States
Endo Pharmaceuticals
Teva Pharmaceuticals USA

Completed

A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering

Stuttering

United States
Nucorion Pharmaceuticals, Inc.
Ligand Pharmaceuticals

Completed

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Chronic Hepatitis B

United States
Semafore Pharmaceuticals
SignalRX Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

Cancer | Advanced or Metastatic Solid Tumors | Solid Cancers

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Hepatitis C, Chronic

United States
Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Completed

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Liver Transplantation | Hepatitis | Carcinoma, Hepatocellular | Cholestasis

United States, Germany
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

Neoplasms | Lymphoma

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Institut Bergonié
Bristol-Myers Squibb; Amgen; Aventis Pharmaceuticals; Sanofi-Synthelabo; Chugai Pharmaceutical

Completed

Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment (PHRC2003)

Digestive System Diseases | Lymphoma | Ovarian Diseases | Pulmonary Disease | Bladder Disease | Prostatic Disease

France
Foresee Pharmaceuticals Co., Ltd.
QPS Holdings LLC; Changchun GeneScience Pharmaceutical Co., Ltd.

Recruiting

Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Puberty; Precocious, Central

United States, China, Taiwan, Puerto Rico
Henan Cancer Hospital
Qilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.

Not yet recruiting

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

HER-2 Negative Breast Cancer
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb

Active, not recruiting

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Oropharynx Squamous Cell Carcinoma

United States
University of Michigan Rogel Cancer Center
Phase One Foundation

Completed

Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma

Glioblastoma Multiforme | Malignant Glioma

United States
University of Michigan Rogel Cancer Center
University of Washington

Completed

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

Non-small Cell Lung Cancer

United States
University of Michigan
University of Michigan Rogel Cancer Center

Completed

Acupressure for Post-Treatment Cancer Fatigue

Fatigue

United States
University of Michigan Rogel Cancer Center
Hoffmann-La Roche

Terminated

Radiation Therapy With Capecitabine in Rectal Cancer

Rectal Cancer

United States
Navitor Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

Completed

Mass Balance Study of NV-5138 in Healthy Male Subjects.

Healthy Volunteers

United Kingdom
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Prostate Cancer

Korea, Republic of
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb

Completed

The SMART CART Study: Health Information Technology

Leukemia, Acute | Leukemia, Lymphoblastic

United States
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb

Completed

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

United States
University of Michigan Rogel Cancer Center
St. Baldrick's Foundation

Terminated

Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients

Cancer | Depression, Anxiety

United States
University of Michigan
University of Michigan Rogel Cancer Center

Completed

Fatigue Reduction Diet (FRD)

Chronic Fatigue

United States
Pavan Reddy, MD

Completed

Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Graft vs Host Disease | Hematologic Malignancies

United States
University of Michigan Rogel Cancer Center
University of Michigan

Terminated

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

Metastatic Colorectal Cancer

United States

Clinical Trials Sponsored by Rigel Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations